- Home
- BAH vs INCY Comparison
BAH vs INCY Comparison
Compare BAH & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAH
- INCY
- Stock Information
- Founded
- BAH 1914
- INCY 1991
- Country
- BAH United States
- INCY United States
- Employees
- BAH N/A
- INCY N/A
- Industry
- BAH Professional Services
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- BAH Consumer Discretionary
- INCY Health Care
- Exchange
- BAH Nasdaq
- INCY Nasdaq
- Market Cap
- BAH 13.9B
- INCY 13.0B
- IPO Year
- BAH 2010
- INCY 1993
- Fundamental
- Price
- BAH $111.51
- INCY $77.73
- Analyst Decision
- BAH Hold
- INCY Hold
- Analyst Count
- BAH 11
- INCY 20
- Target Price
- BAH $131.40
- INCY $77.69
- AVG Volume (30 Days)
- BAH 2.0M
- INCY 1.6M
- Earning Date
- BAH 07-25-2025
- INCY 07-29-2025
- Dividend Yield
- BAH 1.97%
- INCY N/A
- EPS Growth
- BAH 75.51
- INCY 900.04
- EPS
- BAH 8.15
- INCY 4.37
- Revenue
- BAH $11,962,000,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- BAH $2.54
- INCY $13.53
- Revenue Next Year
- BAH $5.33
- INCY $10.38
- P/E Ratio
- BAH $13.68
- INCY $17.79
- Revenue Growth
- BAH 9.25
- INCY 18.87
- 52 Week Low
- BAH $98.95
- INCY $53.56
- 52 Week High
- BAH $190.59
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- BAH 56.12
- INCY 67.13
- Support Level
- BAH $106.47
- INCY $73.81
- Resistance Level
- BAH $109.33
- INCY $78.77
- Average True Range (ATR)
- BAH 3.81
- INCY 2.03
- MACD
- BAH 0.04
- INCY 0.76
- Stochastic Oscillator
- BAH 43.59
- INCY 90.99
About BAH Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.